Since the arrival of COVID-19 vaccines in Canada, information about their availability and use continues to be updated frequently. Recently, bivalent vaccines have been introduced to combat multiple strains of COVID-19 with a single vaccine dose. ISMP Canada has received numerous reports of incidents and concerns related to the labelling of these vaccines. In particular, the inability to differentiate the monovalent and bivalent vaccines resulted in errors of incorrect product and incorrect dose. This bulletin focuses on the labelling of these products, as a key factor contributing to the errors, and shares recommendations for both manufacturers and health care providers.